2nd United Conference of Pharmacy and Health Care Systems

Theme : Coming Soon

Conference on Pharmacy and Health Care Systems, April 2022 @ New Jersey

About The Conference

The 2nd Conference of Pharmacy and Health Care Systems, hosted by United Pharma Journals and Conferences, will take place in the month of April, 2022 @ New Jersey. The Conference Pharmacy and Health Care Systems – 2022 will feature thought-provoking keynotes presentations, plenary talks, poster presentations, panel discussions, special sessions, and professional development opportunities. This conference will address the most up-to-date approaches, developments, novel strategies, and numerous disciplines engaged in Pharmacy, Health care systems, Digital Health, Digital Pharma. The conference also serves as a leading interdisciplinary forum for academics, practitioners, and educators to present and discuss the most recent breakthroughs, trends, and issues in the field of Pharmacy and Health Care Systems as well as practical challenges and solutions.

Pharmacy and Health Care Systems – 2022 welcomes all the academicians, researchers, medical practitioners, principal investigators, CROs, CMOs, investors, and senior executives from the Biotech, Biopharma, Biomedical, Medical Devices, and pharmaceutical industries across the to discuss, share, develop and implement their novel ideas and thoughts.

The conference will provide opportunity for everyone to learn, gain insight, and develop new-fangled concepts that you may practice after the Conference. There will also be several opportunities to network and meet new colleagues from industry and patient organizations, all of which we hope will lead to future successful collaborations. It is unquestionably our goal and ambition for each participant to be enriched in a progressive way, both professionally and personally.

Our Most Valuable Keynote Speakers

Gail Trauco

Advisory Committee Member COVID-19 FDA, Principal CEO The PharmaKon LLC, USA

Hashim Ahmed

Sr. Director-Head Of Formulation And Manufacturing, Avomeen, United States

CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead

Chief Compliance Officer At Engrail Therapeutics | CEO At PDC Pharma Strategy, USA

Jim Hauske
Jim Hauske

President And Founder At Sensor Pharma, United States

Timur Güvercinci
Timur Güvercinci

Director, Head Of External Supply Quality Processes And Development Bei Merck Gruppe Global Quality, Germany

Ravi Kalyanaraman
Ravi Kalyanaraman, Ph.D.

Director, Global Analytical Science & Technology - Pharma & Forensics Bristol Myers Squibb, United States

Danielle Drachmann

Executive Director At Ketotic Hypoglycemia International, Committee Member At The European Health Parliament, Patient Representative At The European Medicines Agency, Rare2030 EURORDIS, Europe

Stephan O. Krause

Head Of Product Quality Group At AstraZeneca Biologics, USA

Marieke Meulemans

CEO GCP Central B.V.,Amsterdam, North Holland, Netherlands

Karmen Trzupek
Karmen Trzupek

Director, Clinical Trial Services At InformedDNA, United States

Detlef Behrens
Detlef Behrens

Managing Director And Co-Founder At Bay Pharma GmbH Greater Kiel Area, Germany

Mathew Cherian
Mathew Cherian

Director & Senior Fellow Pharmaceutical Development, Hospira, A Pfizer Company, United States

Qihan Dong

Director, Chinese Medicine Anti-Cancer Evaluation Program, Sydney Medical School The Faculty Of Medicine And Health, The University Of Sydney, Australia

Li, Fengzhi

Faculty Member At Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, USA

James T. O'Donnell
James T. O'Donnell

Pharmacologist Drug Expert, Associate Professor At Rush Medical College, United States

Gareme Ladds

CEO PharSafer Associates Ltd - Global Leaders In Drug Safety, United Kingdom

Avik Pal
Avik Pal

Founder & CEO, CliniOps, Fremont, California, United States

Liana Kasyan

Founder/CEO And Principal PV Consultant At ETL Pharmacovigilance Center Ltd. Armenia

Eluemuno R Blyden

Founder/CEO At Avril Biopharma, Inc., United States

Sessions and Tracks

  • Pharmaceutical Care & Health Systems
  • Pharmacist in Public Health Care
  • Preventive Medicine
  • Health care and Medical informatics
  • Womens Health care
  • Preventive Medicine and Behavioral Health
  • Health Care and Infectious Disease
  • Nursing and Health Care
  • Psychological Health Care
  • Advanced Health Care Oncology
  • Clinical Pharmacology & Biopharmaceutics
  • Pharmacovigilance and Drug Safety
  • Obesity Health Disorders
  • Advanced Healthcare & Innovations
  • Pediatrics Health Care
  • Neuropharmacology Care
  • Advances in Pharmacological Research
  • Cardio Vascular Pharmacology health care
  • Clinical Pharmacology and drug discovery
  • Psychology and psychiatric Disorder Health Care
  • Pharmaceutical Analysis and Developments
  • Pharmacovigilance & Pharmaceutical Products
  • Industrial & Physical Pharmacy
  • Pharmaceutical Regulatory Science & Developments
  • Healthcare Patient safety
  • Research & Development in pharmacy
  • Health Care Statistics and Research
  • Preventive Medicine and Dermatology
  • Nutrition and Health Care
  • Pharmaceutical Drug Discovery

Previous Keynotes

Founder & CEO | Chief R&D & AI Health Innovation Officer| Chief Digital Health Officer & Chief Strategy Officer @Global DigiAIHealth | Expert Member for Digital Health, AI Health, WHO Geneva.

Marieke Meulemans

CEO GCP Central B.V., Amsterdam, North Holland, Netherlands

CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead

Karmen Trzupek
Karmen Trzupek

Director, Clinical Trial Services at InformedDNA, United States

Ted Barduson

COO, Co-Founder at MedVector Clinical Trials

Clinical Operations | Genentech,, United States

Clinical Researcher | Advancing medicine with Clinical Trial Austin, Texas, United States

Michael Sassano

Founder, Chairman & CEO Somai Pharmaceuticals; Leading Mergers as Founder of Solaris Farms; Investor, Cannabis, GMP Specialist, Alternative Medicine

Basma ElBahrawy
Basma ElBahrawy

Compliance Officer Ad-Interim at Clinart MENA

Ahmed Elgouhary

Vaccines Medical Affairs & PSI Lead, Saudi Arabia at Pfizer

Ongoing Keynotes

Saliha Akhtar
Saliha Akhtar

Strategy & Operations in Global Drug Development, Bristol Myers Sqibb New York City Metropolitan Area

Dr Lia Hunter
Dr Lia Hunter

Consultant Orchard with Director Clinnovate Ltd/ CGX TRAINING Ltd, south Croydon, England, United Kingdom

Boxiong Tang

Executive Director at BeiGene USA Inc

Om Sharma
Om Sharma, MS, PhD

Former Senior Director,
Global Oncology R&D

Sathish Dharani
Sathish Dharani

Assistant Research Scientist College Station, Texas, United States


Virtual Exhibitors


ASTE Pharmaceuticals, Medical & Laboratory Supplies

TGMP Consulting

Conference Registration Charges

  • Keynote/ OCM Registration Not Applicable
  • Speaker Registration 599 USD
  • Delegate Registration 399 USD
  • Student Delegate Registration 199 USD
  • Poster Presentation Registration 249 USD
  • Young Research Forum 249 USD
  • Video Presentation Registration 299 USD

Exhibitor Membership Packages

  • Diamond Registration 6599 USD
  • Platinum Registration 5599 USD
  • Gold Registration 4599 USD
  • Silver Registration 3599 USD
  • Bronze Registration 2599 USD

Sponsor Membership Packages

  • Diamond Registration 7599 USD
  • Platinum Registration 6599 USD
  • Gold Registration 5599 USD
  • Silver Registration 4599 USD
  • Bronze Registration 3599 USD

Sponsorship Addons

  • Session Sponsor 1799 USD
  • Lunch Sponsor 1599 USD
  • Lanyard Sponsor 1299 USD
  • Bag Sponsor 1299 USD

Promotional Addons

  • Banner Promotion 249 USD
  • Video Promotion 349 USD
  • Exclusive Exhibitor Stall 1099 USD
  • 1 Day Exhibitor Stall 699 USD

Who Can Attend

  • Deans, Directors, CEO of an Organization
  • Business Development Managers
  • Chief Scientific Officers
  • R&D Researchers from Biosimilar and Biologic Industries
  • PhD Scholars
  • Professors, Associate professors, Assistant Professors
  • Drug Development Discovery Companies
  • Association, Association Presidents and Professionals
  • Formulation and Pharma Manufacturing Companies
  • Business Entrepreneurs
  • Medical Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Intellectual Property Attorneys
  • Noble laureates in Health Care and Medicine
  • Pharmacists
  • Bio-instruments and Bio-informatics Professionals
  • Research Institutes and members
  • Pharmacy Institutes

Why Choose Us

  • Global & Local Expertise
  • Prospective Attendees
  • Larger worldview of the profession
  • We’re passionate about what we do
  • We focus on your career growth
  • Transparency in Communication
  • Open gateway towards INNOVATION
  • Strong sense of identification
  • Quality without compromise
  • Highly organised and structured scientific programs

Key Takeaways

  • Professional Worldwide
  • International Recognition of Researchers
  • Knowledge into Asset
  • Cognizance of leading Cutting – Edge technologies
  • Publication of Abstracts in preeminent supported journals
  • New Accomplishments with Edu – tech ideas
  • Exposure to the upcoming business trends
  • Free access to our forthcoming International events
  • Certificate of presentation with International signatories

United Pharma Technologies Collaborations and Associations

Gail Trauco
Gail Trauco
Advisory Committee Member COVID-19 FDA, Principal CEO The PharmaKon LLC, USA
Biography: The PharmaKon LLC specializes in clinical pharmaceutical product development and trials. It is a 100% woman owned business led by its CEO/founder Gail Trauco, R.N., BSN-OCN. The PharmaKon partners with biopharmaceutical and biotech companies, investigators, site staff, lab and technology vendors, and regulatory authorities to reinforce patient safety and access throughout every phase of research. All play a part in delivering the quality data that can drive promising compounds forward.
For nearly 30 years, The PharmaKon’s dedicated government and public health services group has successfully delivered clinical research services to various agencies, contractors and nonprofits in both prime contractor and subcontractor capacities within full compliance of all federal contracting requirements. Its services have supported the organizations in conducting therapeutic, vaccine and medical device studies on a global scale across all trial phases and therapeutic areas.

The PharmaKon has a unique understanding and connection to rural healthcare and underserved communities by way of Trauco’s personal experiences growing up on a family farm in her native North Carolina. Despite challenges with generational grief and poverty, Trauco persevered through high school and college at University of North Carolina at Chapel Hill and then began a life and career of her own as an oncology nurse. Trauco worked for the Chief of Surgical Oncology at Duke University Cancer Cener, Dr. Hilliard Siegler, a pioneer in the field of immunotherapy in 1957, whom she credits for her foundation of knowledge about medicine.

A registered Oncology nurse, pharmaceutical trials expert, and long-time Patient advocate, Trauco has spent four decades helping patients navigate the sea of red tape in the American healthcare system. Based just outside Atlanta, she has gained a reputation as a fierce advocate for patient’s rights and for resolving some of the most difficult medical cases in the currently crippled healthcare industry. As a lifelong healthcare professional and frequent on camera expert, Gail Trauco is equal parts Gloria Allred, Erin Brokovich, and Nancy Grace…with a small twist of Dog the Bounty Hunter.

For more information about Gail Trauco and The PharmaKonLLC visit:
Hashim Ahmed
Hashim Ahmed
Head of Formulation and Manufacturing at Avomeen. Wake Forest, North Carolina, United States
Biography: A pharmaceutical product development executive leader with wide experience in CMC/MS&T-product development-R&D expertise with in-depth diversified global technical and management experience. Expert in formulation/process/product development supply management; and quality assurance of pharmaceutical/consumer products. Over 26 years of experience in the United States in major, medium-to-small companies (Roche/Stiefel-GSK/Dr. Reddy's). Consumer Product Development and regulatory expert in a diverse portfolio of APIs and a wide range of dosage forms, with NDA/505b2/generic-ANDA experience.
In-depth experience in small and large molecules (proteins/peptides); orals (tablets, capsules [hard-soft gel]); controlled-modified release formulations; as well as/parenterals dosages. Expert in oral Liquids Emulsions-Suspensions, Lipids, Powders, Topicals, Transdermals, Ocular delivery, Intranasal, Aerosols. SKILLS: Proven Product Development/CMC/Regulatory Leader (26 years in the USA at different pharmaceutical technical and management capacities); currently managing general director at QLife the lead pharma company in Qatar.
Nashwa Nashaat
CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead
Biography: She has dedicated her career to improving the patients’ care and healthcare services. Inspired by the advancement in technology and her personal mission to serve patients, she has co-founded a company where the unmet patient’s needs drive the innovation for personalized technology-based solutions. In her role as a Chief Executive Officer and Co-founder for Nexus eHealth, she is committed to being a catalyst in the adoption of precision medicine through the Technology Enabled Connected Care solutions and building the healthcare technology capabilities, especially in the Middle East and Africa.
Prior to founding Nexus eHealth, being a physician; with PhD in Pediatric Oncology/Hematology, she devoted her passion to improve cancer patients’ lives and affordability of medicine by working with different global medical societies, NGOs and policy makers for more than 18 years. She has also worked for top multinational pharmaceutical, diagnostics and medical devices companies (Novartis, Eli Lilly and Johnson & Johnson) during the last 11 years where she took several global executive leadership roles in R&D, GxP auditing, medical affairs, patients advocacy and support programs, governmental affairs, business development, market access, healthcare policies and digital transformation strategies.

She was honored with 25 global awards for innovation, excellence and patient centricity. She authored more than 20 scientific publications. She serves as technical advisor and organizational leadership coach qualified by Glasgow university. She has been volunteering in different community services in Africa and a member in the Global Camper of Commerce and Industry (GCCI) that support the spirit of entrepreneurship. She is an Egyptian woman who constantly advocates the promotion of equality, diversity and inclusion & woman empowerment across the corporate world and the society as a whole.
Penelope Przekop
Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy
Biography: Penelope Przekop, MSQA, RQAP-GCP is the CEO of PDC Pharma Strategy, a consulting firm that focuses on strategic GxP regulatory and corporate compliance. She currently dedicates half of her time to serving as Chief Compliance Officer for Engrail Therapeutics, Inc. She has 30-plus years of broad and deep pharma industry experience and is known for her creative approaches to developing efficient quality management strategies that enable companies of all sizes to build upon their unique drug development history and strengths while ensuring compliance.
Penelope earned her B.S. in Biology from Louisiana State University and her M.S in Quality Systems Engineering from the Kennesaw State University. She is a frequent industry speaker and writer. She is the author of Six Sigma for Business Excellence (McGraw-Hill). Her upcoming book, 5-Star Career (Productivity Press, fall 2021), will relay how readers can apply the proven science of quality management to career development.
Biography: Executive director at Ketotic Hypoglycemia International. Her work started with the establishment of an international patient association where they are in close collaboration with national and international researchers, have written scientific papers and conducted research projects using a Citizen Science approach. Most recently, she entered the European Health Parliament and the European Medicines Agency as a Patient Representative for patients with rare hypoglycemia diseases. Furthermore, she have been working for EURORDIS (European Organization for Rare Diseases) to develop recommendations for Europes' rare disease policy in the Rare2030 project.
Stephan O. Krause
Stephan O. Krause
Head of Product Quality Group at AstraZeneca Biologics, USA
Biography: Stephan Krause, PhD, is currently Quality Director and PQL Team Leader in Development Quality, AstraZeneca Biologics. He is a results-driven leader with 20 years of technical, managerial, and executive experiences for quality and technical functions within global operations. He is a frequent conference presenter and author and has won multiple industry awards for his publications and leadership in improving industry best practices. Stephan was invited by FDA several times to present an industry perspective to the agency on relevant current topics. He is a member of PDA’s Board of Directors and is co-chair of AMTP Advisory Board and a member of the Advisory Board for Biopharmaceuticals and Regulatory Affairs/Quality.
Marieke Meulemans
Marieke Meulemans
CEO GCP Central B.V., Amsterdam, North Holland, Netherlands
Biography: She is a Founder and CEO of GCP Central since 2012 with over 15 years of experience within the clinical research world, and is the driving force behind the company vision.

•Development of practice-based and effective online GCP training for clinical research professionals.
•Setup and implementation of Learning Management Systems.

Specialties: eLearning development ; online GCP training; training needs analysis; process improvement; training management; blended learning; Good Clinical Practice; Clinical research rules & regulations; Wet Medisch Wetenschappelijk Onderzoek (WMO) training
Biography: Dr Dong was trained as a Physician then pursued a research career after completing his PhD at the University of Sydney. He continued as a Fogarty Fellow at the National Institutes of Health, USA. On returning to Sydney, he was appointed as the Head of the Cancer Biology Group. Currently, he is Associate Professor and the Director of newly-established Chinese Medicine Anti-cancer Evaluation Program at the Medical School in University of Sydney. He has published 81 papers (3,800 citations) in journals with an average Impact Factor of 4.1. He has been the first or senior author on 70% of them. His team was the first to discover that in prostate cancer cells the expression of the native inhibitory gene of phospholipase decreased. This content has been published three times in "Cancer Research" and "Clinical Cancer Research", and has been included in the latest European edition of "Encyclopedia of Cancer".
Biography: Fengzhi Li became a faculty member at Roswell Park Comprehensive Cancer Center (legal name: Roswell Park Cancer Institute, the first cancer institution in the US history and is a US NCI-designated comprehensive cancer center) in 2001 after finishing his postdoctoral training in Dr. Dario C. Altieri’s laboratory at Boyer Center for Molecular Medicine, Yale Medical School where he focused his research on the characterization of the function and expression regulation of a newly discovered antiapoptotic protein named survivin (a novel member of the inhibitor of apoptosis protein family). In 2006 he has been promoted to Associate Professor of Oncology at Roswell Park. As a chief scientist, he leads his lab using the survivin gene as a target and biomarker for targeted drug discovery. He has transitioned his Roswell Park cancer research lab from basic to translational cancer research over the past decade. His current research interests focus on targeted anticancer drug discovery, development and mechanism of action (MOA) studies. His research has been supported through federal agencies (NIH/NCI, DOD) as well as other public/private foundations and partnerships. He has published over 80 publications (h-index, 47 and i10-index, 73) with a total citation of over 13,000 times. He is the editorial board members in several academic journals including J Exp Clin Can Res (2019 IF: 7.068), Am J Transl Res (2019 IF: 3.375) and Int J Mol Sci (2019 IF: 4.556). He is also the Chief Scientific Officer (CSO) of Canget BioTekpharma LLC (www.canget-biotek.com) and helps Canget to develop innovative targeted anticancer drugs (high efficacy with low toxicity) for benefiting cancer patients.
Biography: Graeme Ladds has worked in Global Pharmacovigilance and Medical Affairs for the last 30 years working with many top ten Pharma in senior positions. He has worked in all areas of Pharmacovigilance and has designed and improved many IT solutions to aid both Medical Affairs and Pharmacovigilance. Graeme is also an experienced GCP/PV auditor having audited many Companies globally as well as helping Companies in Regulatory Inspections. He now works in his CRO - PharSafer Associates Ltd
Liana Kasyan
Liana Kasyan
Founder/CEO and Principal PV Consultant at ETL Pharmacovigilance Center Ltd. Armenia
Biography: Founder/CEO and Principal PV Consultant at the ETL Pharmacovigilance Center Ltd., - Pharmacovigilance Instructor at the Open Education Office of the American University of Armenia, - Member of International Society of Pharmacovigilance (ISoP), - International Editorial Board Member for the Journal of Pharmacovigilance and Drug Research (JPADR), - Reviewer of Master Тheses at the Faculty of Public Health of Yerevan State Medical University, - Board Member of Armenian Association of Specialists in Evidence-Based Medicine (AASEBM), - Co-founder of “Do not Harm’’ Health NGO.
Mahendra Singh
Founder & CEO | Chief R&D & AI Health Innovation Officer| Chief Digital Health Officer & Chief Strategy Officer @Global DigiAIHealth | Expert Member for Digital Health, AI Health, WHO Geneva.
Biography: Mahendra is a visionary, revolutionary serial DigitalHealthTechpreneur, Passionate Next Generation Deep Tech Start-up Guru in Digital Health, AI Health &Telemedicine Innovation & Research with an exceptional synergy of Digital HealthTech Business Management Leadership+ Doctor+Engineer +Innovator &Research Scientist.

He is an Expert Member for Digital Health & Innovation, WHO Geneva.

He is working with WHO Partner 30 countries including India in Digital Health AI Health & Telemedicine Innovation.
He is World's Top 30 Most Impactful Digital HealthTech, AI Health Innovation Global Business Leader, Think-Tank, Speaker& Influencer, KOL, Voice of Healthcare & National-International Policymaker for various countries in deep Digital Health, AI Health, Telemedicine, MedTechIoT,Big Data, Blockchain &MedTech with strong 27 Yrs exp as a Most Impactful Global Business Leader.

A Digital Health & AI Health, Telemedicine Innovation Start-up management Guru.

He can predict with scientific evidence basis which Doctor& Hospital are how much Healthy or Not globally to deliver better treatment outcome & Quality Health delivery to Patient or not.

A serial Digital HealthStartup Founder &CEO, MD, COO, SVP, Director, Board Member &Advisory Board Member.

In his 27 Years exp he founded, setup, worked, built as successful serial DigitalHealthPreneur more than 9 out of his 16 Global Digital Health start-ups from Israel, India, US, UK, Germany & China from scratch Concept to Commercialization converted to Multi-Million$ MNC in an Impossible ecosystem from India to Global.

He launched 90 Innovative Nextgen Digital Health Technologies with 200 Products &Solns in next Gen innovative Healthtech driven by cutting-edge Digital Health,AI Health,Telemedicine & MedTech created tractions of 500 Million Patients globally.
60+ Clinical Trials,400+ Treatment procedures in Top10 medical super specialities including NCD. Transforming Healthcare accessible, affordable to all through disruption & Digital Health AI Health & Telemedicine Innovation for Quality Health Delivery Treatment outcome.

A game-changer, developed novel solution to solve a complex problem in Prevention, early detection, complete disease control &management in Covid19, Top20 Cancer, COPD, Diabetes, Heart & Mental Health.

Created huge value-based business on the basis of his own entrepreneur management skills.

He never give up, alway go ahead with strong will power, determination& Passion to achieve Goal.

He THINK OUT OF BOX with unique Profitable Business management with double-digit sustainable growth approach.
Ted Barduson
Ted Barduson
COO, Co-Founder at MedVector Clinical Trials
Biography: Commercially minded, and accomplished executive with extensive management experience leading all aspects of company success in the development of profit-generating strategies within start-up, turnaround, and industry-leading healthcare companies. Experience in identifying funding sources, merger and acquisition opportunities, and revenue-generating business strategies.
His professional success is due to being a responsive, approachable leader that creates opportunities for my team.
Extensive industry relationships with C-Suite executives and decision-makers at the health system and vendor partner levels. Ability to drive vision into strategic ideas, via close coordination with the management team, stakeholders, and C-level executives.

Some of his career achievements include:
● President and General Manager leading successful private equity exit via a transformation change to recurring software revenue service model, delivering yearly revenue growth of 7%, driving 11% profits, 68% gross margin, and a 166% increase in EBIDTA.
● President of La Jolla Wellness Studio and the patented MyoMetrix Method driving partnership with VEBA Health Plan of 200,000 members of teachers, police, and fire employees in southern California.
● Led sales and support driving commercial company growth from $10M revenue with 450 employees to $130M revenue with 3,000 employees, decreasing sales cycle from 11 months to 88 days, and increasing average customer size from $140,000/year to $525,000/year.

Specialties: Visionary, Strategy, Execution,Turnaround, Change,Cost Analysis,Reduction, and Control;Sales and Marketing Team Building;Customer/Company Profitability;Deal Structuring and Negotiating Skills;Growth Management and Business Development;Product Development and Rollout;Strategic/Tactical Partnership, Development;Investor, Analyst & Board Relations,Strategic Planning & Execution,Operations Management, P&L Administration, Revenue & Profit Growth,Budget & Cost Control,Private Equity,Nationally recognized public speaker,Change Management,Leadership & Team Building, Market Positioning.
Michael Sassano
Michael Sassano
Founder, Chairman & CEO Somai Pharmaceuticals; Leading Mergers as Founder of Solaris Farms; Investor, Cannabis, GMP Specialist, Alternative Medicine
Biography: Although Michael Sassano’s exciting career has led him to be involved in the fast-paced worlds of international real estate development, high-level banking, and cutting edge tech-investing, it is the cannabis space where he has shined the brightest. Michael is well known as one of the original movers and shakers in this sector, celebrated prominently in both mainstream business and cannabis media as an authority on large-scale cannabis cultivation, a pioneer of technology that affects entire markets, and an internationally respected expert on predicting long term industry trends. You can read about his advice's and progress here: https://www.somaipharma.eu/news
In July 2020, Michael led a merger of the cannabis cultivation company he built, Solaris Farms, with The Sanctuary, a local Las Vegas brand operating two dispensaries and an extraction facility. In four years with it's beginnings in private equity, Michael was able to build Solaris out from a bare lot of land into one of the largest and most well respected cannabis cultivation operations in the state of Nevada, and then further merged it into one of the top ten vertically integrated cannabis companies in the state. Michael remains on the advisory board and will help sell the new vertical to a larger company in the future.

Michael has otherwise shifted focus to his role as CEO and Chairman of the Board for Somai Pharmaceuticals LTD, an Ireland-based company that focuses on the cultivation and extraction of cannabis, and producing EU-GMP certified cannabinoid formulations for pharmaceutical distribution. Taking with him the superior cultivation and product development knowledge learned while operating a successful company in the hyper competitive western U.S. market, Somai will be one of the first American-run companies operating across legal European markets.

Michael is currently building scalable high out-put cultivation and extraction facilities in various strategic countries in Europe. The idea is to carefully develop processes for scalability and get proper registrations in order to expand as new countries legalize medical cannabis and new markets and demographics become available. The flexibility of his methods are intended to help mitigate any potential issues of government adoption by opening up avenues for adaptation and expansion as the EU market develops. As the continent ultimately comes fully online, Somai will be positioned as a top global pharmaceutical distributor of medical-grade, EU-GMP-certified cannabis.

Submit Manuscript

Manuscript Details

Author Details